Objective: To explore the feasibility of low-fat spreads as vehicles for folic acid (FA) fortification by determining the acute absorption of FA from a fortified spread. Design: Double blind, crossover study to test each of the following treatments administered at 1-weekly intervals: (A) 20 g lowfat (40%) spread fortified with 200 mg FA and a placebo tablet; (B) 20 g low-fat placebo spread and a 200 mg FA tablet; (C) 20 g low-fat placebo spread and a placebo tablet. Subjects: A total of 13 male volunteers, aged 31.8713.2 y. Main outcome measures: Plasma total folate concentrations, measured before and up to 10 h after each treatment (n ¼ 10 samples per treatment). Results: Plasma folate concentrations were significantly increased compared with baseline values 1 h after administration of the FA tablet, and 1.5 h after the FA spread, and remained significantly higher than the baseline values for up to 7 h after both treatments. The maximum plasma folate response (R max ), corrected for baseline values and 'placebo response', was established between 1 and 3 h postprandially in response to both FA spread and FA tablet, and no significant difference in R max was found between the two treatments (13.4 vs 14.4 nmol/l, P ¼ 0.9). The acute absorption of FA from fortified spread relative to that from the tablet, calculated on the basis of area under the plasma folate response curve, was 67% (P ¼ 0.04). Conclusion: The absorption of FA from fortified low-fat spread, although lower than from a tablet, is effective. These results suggest that low-fat spreads, typically associated with fat-soluble vitamin fortification, may also be considered feasible as vehicles for FA fortification.
Introduction
The problem of maintaining an optimal folate status in the population has been the focus of considerable attention in the recent years. Intervention studies have established conclusively that periconceptional supplementation with folic acid (FA) has a preventative effect on both the recurrence and first occurrence of neural tube defects (NTDs) (MRC Vitamin Study Research Group, 1991; Czeizel & Dudas, 1992) . There is also accumulating evidence to suggest that optimal folate status may have a role in the prevention of vascular disease, through preventing the accumulation of homocysteine (Tucker et al, 1996; Ward et al, 1997; Jacques et al, 1999) , elevated plasma levels of which constitute an independent risk factor for occlusive vascular diseases (Eikelboom et al, 1999) . Furthermore, evidence from epidemiologic, animal and human studies strongly suggests that low folate status appears to enhance carcinogenesis, most notably in the colorectum, whereas folate supplementation appears to be protective (Choi & Mason, 2000) . However, the diet currently consumed by people even in the most affluent and developed countries within Europe does not provide adequate levels of folate to ensure an optimal status of the vitamin for protection against such diseases. Reported dietary folate intakes of adults in different countries range between 168 and 326 mg/day, with many adults failing to meet even current folate recommendations (De Bree et al, 1997) , which are likely to be revised upwards in the near future. There is a need, therefore, to improve dietary folate intakes of healthy European populations.
To improve folate intake and status in the population, three health promotion strategies are considered: (1) nutrition education of the public to increase the consumption of foods naturally rich in folates; (2) supplementation with FA; (3) fortification of food with FA. Whereas the effectiveness of the first two strategies could easily be compromised by poor compliance of the target groups, FA fortification is much more likely to be successful (McNulty et al, 2000) . Recent evidence from the US showing a reduction in the prevalence of NTDs by 19% (Honein et al, 2001) , since the introduction of a mandatory FA-fortification programme has supported the effectiveness of this approach. Few other countries have introduced similar policies, and although it is a matter under consideration in the UK and elsewhere, it remains controversial (McNulty, 2001 ). In the absence of a mandatory policy, there is a justifiable demand for a greater range of FAfortified products, particularly given the well-documented poor bioavailability of the vitamin from natural food folate sources compared with the synthetic form (FA) present in fortified foods .
Low-fat spreads are widely consumed and are typically fortified with vitamins A and D. Therefore, there is a possibility to extend their current fortification profile to include FA. However, the effectiveness of this option has never been scientifically determined. The aim of the present study was to explore the feasibility of low-fat spread as a vehicle for FA fortification by comparing plasma folate responses following ingestion of fortified and nonfortified spread. In addition, we aimed to determine the relative absorption of FA from fortified spread with an equivalent amount of the vitamin provided as an FA tablet.
Methods

Subjects
Ethical approval for the study was granted by the Research Ethical Committee of the University of Ulster and volunteers gave written informed consent. Male volunteers (n ¼ 20) aged 18-60 y were recruited from the staff and student population of the University of Ulster at Coleraine. Exclusion criteria were implemented to avoid the inclusion of subjects in the study who could potentially give an abnormal response to the ingested FA. The following categories of subjects were excluded from participation in the study: those with a history of hepatic, gastrointestinal, renal, vascular, haematological or neuropsychiatric disease; those who were taking FA containing supplements or medicines known to interfere with folate metabolism (aspirin, antiacids, aminopterin, pyrimethamine, phenytoin, methotrexate, sulphasalazine, phenobarbital, primidone); those homozygous for the C677T (so-called thermolabile) variant of the methylenetetrahydrofolate reductase (MTHFR) gene; those with high plasma homocysteine concentration or low status of folate or related B vitamins (Table 1) .
Study design, treatments and sampling Subjects were initially placed on a presaturation regime (in order to minimise intersubject differences in baseline folate concentrations) consisting of 5 mg FA per day for 1 week, b Clinical biochemistry reference ranges are given for all parameters except for plasma total homocysteine where the cutoff for hyperhomocysteinemia defined by Kang et al (1992) has been used.
followed by two FA-free days. In a crossover design, subjects then received three different treatments in random order with an interval of 1 week between each test day. During the interval between treatments, subjects were again placed on the presaturation regime with high-dose FA. On each test day, subjects consumed (under supervision) one of the following treatments as a part of their breakfast early in the morning after an overnight fast: (A)20 g low-fat (40%) spread fortified with 200 mg FA and a placebo tablet; (B)20 g low-fat (40%) placebo spread and a 200 mg FA tablet; (C)20 g low-fat (40%) placebo spread and a placebo tablet.
The spread was applied to two slices of toast, and the tablet was consumed after the first slice of toast. The placebo and FA-fortified spreads were produced by Unilever (Vlaardingen, The Netherlands), who performed shelf life tests and established that FA in the spread was stable for at least 12 weeks.
During each of the test days, subjects were provided with an identical, specially prepared low folate diet (Table 2) . Fasting, which is reported to produce a considerable increase in plasma folate concentration (Pietrzik et al, 1990) , was avoided. The low folate diet was comprised of breakfast, two snacks and lunch, and provided two-thirds of energy requirements for male subjects with a sedentary lifestyle (Department of Health, 1991). The lunch meal was preprepared in one batch and kept frozen at -201C for the duration of the study. To reduce the folate content, all food products included in the lunch meal were boiled three times, with the water discarded after each boiling. The dish was then made more palatable by seasoning and stir-frying before serving. A duplicate portion of the low folate diet (which included breakfast, two snacks and a lunch dish) was analysed for folate content. The FA content of the fortified spread, the placebo spread, the FA tablet and placebo tablet was also determined as described below.
Subjects were cannulated and blood was taken before the consumption of test treatments and afterwards at regular intervals over a period of 10 h (0.5, 1, 1.5, 2, 2.5, 3, 5, 7 and 10 h). Blood samples were collected into foil-wrapped Monoject tubes with EDTA (Sherwood, UK). The samples were immediately placed on ice, and plasma was separated by centrifugation (2000 Â g, 10 min) within 30 min and stored at À801C until analysis. All samples collected from each subject (10 Â 3 days) were analysed in one assay to remove inter-assay measurement variability.
Analytical methods
The folate content of plasma, red cells and FA tablet was determined using a Lactobacillus casei microbiological assay (Molloy & Scott, 1997) , adapted to a microtiter plate procedure and carried out by a robotic system (Hamilton, Bonaduz). Plasma vitamin B 12 concentration was analysed by the method of Kelleher and O'Broin (1991) . Plasma total homocysteine was measured by Abbott Imx FPIA (Leino, 1999) . Erythrocyte aspartate aminotransferase activation coefficient (index of vitamin B 6 status) and erythrocyte glutathione reductase activation coefficient (index of riboflavin status) were measured by enzyme assay on the Cobas Fara centrifugal analyser (Roche Diagnostics, Welwyn Garden City, UK) according to the procedure of Mount et al (1987) . Plasma pyridoxal phosphate was determined by HPLC using fluorescent detection (Bates et al, 1999) . Quality control was provided by pooled plasma and erythrocyte samples aliquoted into small portions and stored at À801C. MTHFR genotype was determined by polymerase chain reaction amplification followed by HinF1 restriction digestion (Frosst et al, 1995) . The total folate content of the low folate diet was measured in a duplicate portion by microbiological assay after thermal extraction and trienzyme treatment according to the procedure of Tamura et al (1997) . The folate content of the FA-fortified spread and the placebo spread was determined by microbiological assay after hexane extraction according to Eitenmiller and Landen (1999) .
Statistical analysis
Statistical analyses were performed by DataDesk, version 6 (Data Descriptions Inc.) statistical package. Plasma folate results were positively skewed, therefore all calculations were performed with log-transformed values, followed by back transformation as geometric mean (GM) for reporting. The differences in plasma folate concentrations between different time points within one treatment were evaluated by repeated measures analysis of variance with Scheffe post hoc test. Maximum plasma folate response (R max ) after both FA treatments was determined by inspection of individual values at different time points. Plasma folate response vs time was plotted and area under the plasma response curve (AUC) was determined by the Trapezoidal method (Altman, 1991) . This involved the sum of the trapezoidal area of each time frame (see Figure 1 ). The differences in R max and AUC between treatments were assessed by paired t-test. For all statistical calculations Po0.05 was accepted as significant.
Results
Analysis of the FA content of the spreads and tablets just before the start of the study showed undetectable amounts of folates in placebo spread and tablets, and a folate content of 206715 mg/20 g portion for fortified spread (n ¼ 10 measurements) and 205722 mg for FA tablets (n ¼ 8 measurements).
Of the initially recruited subjects (n ¼ 20), 13 were eligible to participate in the study. Baseline subject characteristics of this group are given in Table 1 . Folate, parameters of B vitamin status and plasma total homocysteine concentrations of all subjects were within normal reference ranges. Results are presented as geometric means (25-75% ranges); n=13. AF20 g low-fat (40%) spread fortified with 200 mg FA and a placebo tablet. BF20 g low-fat (40%) placebo spread and a 200 mg FA tablet. CF20 g low-fat (40%) placebo spread and a placebo tablet. Significantly different from time 0 h within a treatment group by repeated measures analysis of variance, Scheffe post hoc test (*Po0.05; **Po0.001;***Po0.0001). 
Time (h) Plasma folate response (nmol/L)
A B C Figure 1 Plasma folate response corrected for baseline values. Each point represents the median value for 13 subjects who received all three treatments in random order: AF20 g low-fat (40%) spread fortified with 200 mg FA and a placebo tablet. BF20 g low-fat (40%) placebo spread and a 200 mg FA tablet. CF20 g low-fat (40%) placebo spread and a placebo tablet.
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Plasma folate concentrations at baseline and at different time points during the 10-h test period after treatments are presented in Table 3 . Plasma folate concentrations at baseline were not significantly different among the three treatments (one-way ANOVA, P ¼ 0.8). Compared with baseline, plasma folate concentrations showed a significant response earlier after administration of the FA tablet than after the FA-fortified spread (1 h vs 1.5 h postprandially), and remained significantly higher than the baseline value for up to 7 h after both FA treatments. The maximum rise in plasma folate concentrations varied between 116À216 and 127-222% of baseline values after consumption of the FA spread and FA tablet, respectively. Unexpectedly, there was a tendency for plasma folate concentration to increase after administration of placebo treatment (placebo spread+place-bo tablet), an effect which reached significance at 5 and 7 h compared with baseline. In all three treatment groups, plasma folate concentrations had returned to baseline values by 10 h.
The response of plasma folate to each of the three treatments, calculated by subtracting the individual baseline plasma folate concentrations from the value at each time point, is shown in Figure 1 . Again, a small, but detectable response was established in response to the placebo treatment. In order to account for this 'placebo effect', plasma folate values in response to placebo treatment were subtracted from the corresponding plasma folate values for FAfortified spread and FA-tablet treatments on an individual basis. R max for both FA treatments was established between 1 and 3 h, but most commonly at 2.5 h postprandially. No significant difference in R max was found between the response to FA-fortified spread and that of the FA tablet at 2.5 h postprandially (GM, 13.4 vs 14.4 nmol/l, P ¼ 0.9). The AUC for plasma folate response calculated up to 7 h postprandially was found to be significantly higher after consumption of the FA tablet compared with FA-fortified spread (P ¼ 0.042, Figure 2) . In relative terms, the AUC after FA-fortified spread was determined to be 67% of that after administration of an equal dose of FA as a tablet.
Discussion
In the current study, we determined the absorption of FA from fortified spread in order to explore the feasibility of low-fat spreads as vehicles for FA fortification. Our results reveal that plasma folate concentrations were significantly increased for up to 7 h in response to both FA-fortified spread and FA tablet, and the maximum response was not significantly different between treatments. Therefore, our results suggest that the absorption of FA from the spread, and thus its bioavailability, is effective. However, when AUC was compared between the two treatments, a significantly lower response (67%) was observed for FA-fortified spread compared with the tablet. These findings indicate that the spread, although less effective than tablets as a means of providing additional FA, could be considered a feasible vehicle for FA fortification.
There are only a limited number of studies investigating the bioavailability of FA added to different foods, and these are inconsistent. Colman et al (1975) , on the basis of shortterm changes in plasma folate of South African pregnant women, demonstrated that the absorption of FA added to maize and bread was 60 and 30%, respectively, compared to FA supplements. Much more recent studies using stable isotope methodology found that the FA in fortified cereal products was as bioavailable as FA supplements in healthy adults (Pfeiffer et al, 1997) . Consistent with the latter report were the results of red cell folate responses to long-term feeding trials, carried out in this centre, which again showed very similar responses for FA-fortified breakfast cereal products and FA supplements (Cuskelly et al, 1996) . However, it is difficult to draw comparisons between various studies because they have used different methodological approaches, different study protocols, and more importantly, different foods as a vehicle for FA. No other study to our knowledge has examined the bioavailability of FA from fortified spread or similar fat-based food. Furthermore, in the current investigation, we used numerous time points (10 in the course of 10 h), with frequent sampling around the time of the expected folate peak. This approach enabled a more precise estimation of the overall response to treatment compared to other studies. For example, Colman et al (1975) monitored the changes of plasma folate values for only 1-2 h postprandially, and therefore may have underestimated the extent of the response to a given treatment. To avoid fasting, which is reported to increase plasma folate (probably by interrupting the enterohepatic circulation, a major elimination route for folates, Pietrzik et al, 1990 ), a palatable low folate (but energy adequate) diet was prepared for the test days. Providing subjects with a standard low folate diet on each of the 3 test days was considered to be a much more physiological approach compared with the use of a folate-free liquid formula diet adopted by other Acute absorption of folic acid K Pentieva et al investigators (Prinz-Langenohl et al, 1999) . In addition, the latter approach has the potential to compromise compliance by being unacceptable to the subjects.
The explanation for the lower plasma folate response (AUC) to the fortified spread compared with an equal dose of FA provided as a tablet is unclear. As we found excellent reproducibility of the FA content between individual portions of the product, we can outrule the obvious explanation that the FA may not have been uniformly dispersed throughout the spread. In addition, we think that it is unlikely that the differences in plasma folate response between the two FA-treatments were the result of our methodological approach for a number of reasons. First, we minimised the influence of factors that could reduce folate absorption by screening all volunteers to exclude subjects who could potentially have responded abnormally to ingested FA. Moreover, to standardise baseline plasma folate concentrations, all volunteers were placed on a 1-week presaturation regime with FA prior to starting the study and between each of the three treatments. The effectiveness of this approach as a standardisation procedure is indicated by the fact that baseline plasma folate did not differ between treatments, which were administered in random order to each subject. Thus, differences in plasma folate response to the two FA-treatments cannot be explained by differences in baseline folate concentrations. One possible explanation for the difference in response between treatments is that the rate of emulsification and hydrolysis of the fat phase of the spread may have delayed the release of FA for absorption. This is consistent with the difference in the response pattern between the two treatments, that is the increase in plasma folate concentration occurred earlier after administration of the FA tablet compared with that following the FA-fortified spread. However, our results showed not only that the response pattern between the two treatments was different, but that there was a lower overall response (ie AUC) following the ingestion of the FA-fortified spread, the explanation for which remains unclear.
The small increase observed in plasma folate concentrations after placebo treatment was unexpected. One reasonable explanation for this 'placebo effect' may be that it was because of folates present in the meals provided over the period of measurement. We think that this is unlikely, however, because there was no increase in plasma folate (in any of the three treatment groups) in response to the lunch meal that delivered the greatest amount of food folate (70 mg of a total of 90 mg) over the period of measurement. A more likely explanation for the 'placebo effect' is that the breakfast consumed by the subjects contained a relatively high amount of fat, which may have stimulated bile acid secretion into the gut, a known reabsorption route for folates (Chanarin, 1979) . Therefore, the increase in plasma folate seen in response to the placebo treatment in this study may be the result of the reabsorption of excreted bile folate. In support of this explanation are the results of a previous study from this centre using a similar protocol (unpublished), which differed from the current placebo treatment only in terms of the amount of the spread provided in the breakfast meal (10 vs 20 g in the current study). The previous study showed no increase in plasma folate in response to placebo treatment, with plasma folate concentrations being maintained at baseline levels throughout the 10 h period of measurement. Whatever the reason for the placebo effect, we have corrected for it in our analysis.
In summary, this study shows that the absorption of FA from fortified spread, although lower than that from an equivalent dose provided in a tablet, is effective. This indicates that such spreads, which are not typically associated with FA fortification, could be considered feasible vehicles by which additional FA can be provided. Most European countries have no mandatory policy with respect to FA fortification, and the range of products fortified on a voluntary basis is very limited. This means that the majority of European consumers do not benefit from FA fortification. Expanding the range of products fortified with FA would provide consumers with a greater choice of products to help achieve the desired increase in FA intake. Fortification of spreads with FA, not only offers a means of reaching a wider proportion of the population without requiring any major change in dietary habits, but delivers the vitamin in a highly bioavailable form. Further studies are warranted in order to confirm the effectiveness of FA-fortified spreads in terms of improving long-term folate status.
